Song Quan

Purpose: To determine whether day 2 to day 3 developmental trajectories improve day 3 embryo ranking and selection compared with day 3 cell number alone, thereby offering better prognostic information for cleavage-stage embryos, including fast-cleaving embryos whose developmental potential remains uncertain. Design: This retrospective multicenter study (2016–2024) developed a ranking framework using 27,002 embryos from one center and validated it in 1691 fresh day 3 single embryo transfers across three centers (maternal age ≤ 38 years; embryos derived from two pronuclei, with fragmentation ≤ 10%, symmetric, and no multinucleation for confounder control). Developmental trajectories combined day 2 and day 3 cell numbers. Mixed-effects logistic models assessed trajectory–blastulation associations; post hoc comparisons consolidated trajectories into four ranking categories. Validation used trend tests between ranking levels and pregnancy rates, multivariable mixed-effects logistic model to estimate adjusted odds ratios (aORs) between ranking levels, and AUC for pregnancy prediction. Results: Trajectory analysis reversed the advantage of day 3 8-cell over 9–16-cell embryos (30.7% vs. 24.2% high-quality blastulation; P < 0.001), with Normal_Fast (4 → 9–16) achieving the highest rate (40.7%), significantly higher than Normal_Normal (4 → 8; 35.1%; P < 0.001). Trajectories were consolidated into a four-category ranking: (1) Normal_Fast (4 → 9–16); (2) Normal_Normal (4 → 8); (3) Normal_Slow (4 → 6–7), Slow_Normal (< 4 → 8), Fast_Normal and Fast_Fast (> 4 → 8–16); and (4) all others. Ranking 1 had a higher likelihood of clinical pregnancy than ranking 2 (aOR = 2.06 [1.05–6.82]), although this validation was limited by sample size ( n = 24). Trajectory outperformed day 3 cell number in predicting high-quality blastocyst (AUC 0.776 vs. 0.729; P < 0.001) and clinical pregnancy (AUC original 0.619 vs. 0.596, P = 0.02; down-sampled 0.682 vs. 0.618, P = 0.016). Conclusions: For women ≤ 38 years undergoing fresh day 3 single embryo transfer, developmental trajectories from day 2 to day 3 improve embryo ranking and selection with other morphological features controlled (two pronuclei, fragmentation ≤ 10%, symmetry, no multinucleation). The 4 → 9–16 pathway emerges as potentially optimal, though requiring further validation. This dual-day framework treats both cell numbers as interdependent markers, where day 2 status redefines the priority of day 3 cell number, rather than serving only as a secondary criterion.

Background and aims: To identify novel biomarkers and therapeutic targets for polycystic ovary syndrome (PCOS) using integrated bioinformatics approaches. Methods: We integrated two microarray datasets (GSE34526, n = 10; GSE137684, n = 12) and validated findings in an independent RNA-seq dataset (GSE168404, n  = 10). We employed weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and three machine learning algorithms to investigate differentially expressed genes (DEGs) and module genes. Results: We retrieved gene expression datasets GSE34526 and GSE137684, utilizing the limma package to identify DEGs between PCOS and control subjects. WGCNA revealed 122 upregulated and 431 downregulated genes across 11 distinct modules, with the darkslateblue module containing 143 genes showing the highest Pearson correlation coefficient. Enrichment analyses indicated significant associations with pathways related to lipid metabolism, glucose metabolism, neutrophil regulation, and various immune functions. These findings were validated in an in vitro PCOS cell model. Conclusions: Our study highlights SEC14L5 as a key differentially expressed gene in PCOS, providing a promising target for clinical research and treatment of PCOS patients.

Background: Clarifying the impact of day-3 cell number on blastulation and subsequent pregnancy outcomes is essential for optimizing blastocyst selection criteria and refining embryo assessment protocols. While slow cleavage on day 3 is well-recognized as detrimental, the prognostic value of rapid cleavage (>8 cells) remains ambiguous. Methods: This retrospective cohort study (January 2015–April 2024) included 64,853 embryos undergoing blastocyst culture (Cohort 1) and 2,669 single-blastocyst frozen embryo transfer (FET) cycles (Cohort 2) at a large tertiary assisted reproduction center. Cohort 1 examined the association between day-3 cell number and blastulation potential. Cohort 2 evaluated clinical pregnancy, live birth, and miscarriage rates following single-blastocyst transfer using multivariable logistic regression adjusted for confounders. Embryos were stratified by maternal age ( 1.4; 95% CIs excluded 1). This pattern was consistent across female age subgroups. In Cohort 2, however, the advantage of 11–16-cell embryos translated into superior pregnancy and live birth rates only in younger women receiving top-quality blastocysts versus 8-cell embryos (76.5% vs . 63.0%, P = 0.002, aOR = 1.95 [1.30–2.96]; 61.2% vs . 51.2%, P = 0.034, aOR = 1.58 [1.10–2.30]). Conversely, in older women with non-top-quality blastocysts, 11–16-cell embryos predicted lower pregnancy and live birth rates (26.5% vs . 51.0%, P = 0.023, aOR = 0.40 [0.15–0.97]; 14.7% vs . 38.5%, P = 0.019, aOR = 0.32 [0.10–0.89]). The 9–10-cell embryos generally showed outcomes comparable to 8-cell embryos, except for a reduced live birth rate in the older, non-top-quality blastocyst subgroup (23.9% vs . 38.5%, P = 0.047, aOR = 0.51 [0.26–0.98]). Conclusion: Day-3 cell number serves as a context-dependent prognostic indicator for optimizing blastocyst selection. For young women with top-quality blastocysts, ≥11-cell embryos are the strongest candidates; conversely, 8-cell embryos appear optimal for older women with non-top-quality blastocysts.

Background: Fibrogenesis within ovarian endometrioma (endometrioma), mainly induced by transforming growth factor-β (TGF-β), is characterized by myofibroblast over-activation and excessive extracellular matrix (ECM) deposition, contributing to endometrioma-associated symptoms such as infertility by impairing ovarian reserve and oocyte quality. However, the precise molecular mechanisms that underpin the endometrioma- associated fibrosis progression induced by TGF-β remain poorly understood. Methods: The expression level of lysine acetyltransferase 14 (KAT14) was validated in endometrium biopsies from patients with endometrioma and healthy controls, and the transcription level of KAT14 was further confirmed by analyzing a published single-cell transcriptome (scRNA-seq) dataset of endometriosis. We used overexpression, knockout, and knockdown approaches in immortalized human endometrial stromal cells (HESCs) or human primary ectopic endometrial stromal cells (EcESCs) to determine the role of KAT14 in TGF-β-induced fibrosis. Furthermore, an adeno-associated virus (AAV) carrying KAT14-shRNA was used in an endometriosis mice model to assess the role of KAT14 in vivo. Results: KAT14 was upregulated in ectopic lesions from endometrioma patients and predominantly expressed in activated fibroblasts. In vitro studies showed that KAT14 overexpression significantly promoted a TGF-β-induced profibrotic response in endometrial stromal cells, while KAT14 silencing showed adverse effects that could be rescued by KAT14 re-enhancement. In vivo, Kat14 knockdown ameliorated fibrosis in the ectopic lesions of the endometriosis mouse model. Mechanistically, we showed that KAT14 directly interacted with serum response factor (SRF) to promote the expression of α-smooth muscle actin (α-SMA) by increasing histone H4 acetylation at promoter regions; this is necessary for TGF-β-induced ECM production and myofibroblast differentiation. In addition, the knockdown or pharmacological inhibition of SRF significantly attenuated KAT14-mediating profibrotic effects under TGF-β treatment. Notably, the KAT14/SRF complex was abundant in endometrioma samples and positively correlated with α-SMA expression, further supporting the key role of KAT14/SRF complex in the progression of endometrioma-associated fibrogenesis. Conclusion: Our results shed light on KAT14 as a key effector of TGF-β–induced ECM production and myofibroblast differentiation in EcESCs by promoting histone H4 acetylation via co-operating with SRF, representing a potential therapeutic target for endometrioma-associated fibrosis.

Background: Plasma microRNAs act as biomarkers for predicting and diagnosing diseases. Reliable non-invasive biomarkers for biochemical pregnancy loss have not been established. We aim to analyze the dynamic microRNA profiles during the peri-implantation period and investigate if plasma microRNAs could be non-invasive biomarkers predicting BPL. Methods: In this study, we collected plasma samples from patients undergoing embryo transfer (ET) on ET day (ET0), 11 days after ET (ET11), and 14 days after ET (ET14). Patients were divided into the NP (negative pregnancy), BPL (biochemical pregnancy loss), and CP (clinical pregnancy) groups according to serum hCG levels at day11~14 and ultrasound at day28~35 following ET. MicroRNA profiles at different time-points were detected by miRNA-sequencing. We analyzed plasma microRNA signatures for BPL at the peri-implantation stage, we characterized the dynamic microRNA changes during the implantation period, constructed a microRNA co-expression network, and established predictive models for BPL. Finally, the sequencing results were confirmed by Taqman RT-qPCR. Results: BPL patients have distinct plasma microRNA profiles compared to CP patients at multiple time-points during the peri-implantation period. Machine learning models revealed that plasma microRNAs could predict BPL. RT-qPCR confirmed that miR-181a-2-3p, miR-9-5p, miR-150-3p, miR-150-5p, and miR-98-5p, miR-363-3p were significantly differentially expressed between patients with different reproductive outcomes. Conclusion: Our study highlights the non-invasive value of plasma microRNAs in predicting BPL.

Objective: This study aimed to evaluate the association between blood heavy metal (zinc (Zn), copper (Cu), lead (Pb), and cadmium (Cd)) concentrations and spontaneous abortion (SA) and recurrent pregnancy loss (RPL) and explore the possible endocrine dysfunction associated with it.Methods: A literature search was performed in the PubMed, Embase, Cochrane Library, and Web of Science databases up to April 2023. The overall effects were expressed as the standard mean difference (SMD). Subgroup analysis was performed according to the type of abortion (SA or RPL). Stata 16.0 was utilized for data analysis.Results: Based on the integrated findings, abortion women showed significantly lower Zn (SMD = −1.05, 95% CI: −1.74 to −0.36, p = 0.003) and Cu concentrations (SMD = −1.42, 95% CI: −1.97 to −0.87, p <0.001) and higher Pb (SMD = 1.47, 95% CI: 0.89–2.05, p <0.001) and Cd concentrations (SMD = 1.15, 95% CI: 0.45–1.85, p = 0.001) than normal pregnant women. Subgroup analysis showed that Zn and Cu deficiency and Cd and Pb exposure were significantly (p <0.05) associated with RPL, whereas Cu deficiency and Cd and Pb exposure were significantly (p <0.05) associated with SA.Conclusion: Zn and Cu deficiencies and Pb and Cd exposure were associated with abortion. Endocrine dysfunction, such as insulin resistance, vitamin D insufficiency, and abnormal thyroid and sex hormone concentrations, is thought to be involved in heavy metal-related abortion.

To clarify the effect of next-generation sequencing (NGS)-based preimplantation genetic testing for aneuploidy (PGT-A) combined with trophectoderm (TE) biopsy on the pregnancy outcomes of idiopathic recurrent pregnancy loss (iRPL) and idiopathic recurrent implantation failure (iRIF), we conducted a retrospective cohort study of 212 iRPL couples and 66 iRIF couples who underwent PGT-A or conventional in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment. The implantation rate (IR) per transfer (64.2%), clinical pregnancy rate (CPR) per transfer (57.5%), and live birth rate (LBR) per transfer (45%) of iRPL couples of the PGT-A treatment group were significantly higher (p < 0.05) than those of the conventional IVF/ICSI group (IR per transfer,38.2%; CPR per transfer,33.3%; LBR per transfer, 28.4%), whereas the pregnancy loss rate (PLR) per transfer was similar between the two groups. These effects were also significant (p < 0.05) in iRPL couples with advanced maternal age (AMA, ≥35 years), whereas no significant differences were found in clinical outcomes between the PGT-A and conventional IVF/ICSI groups in younger iRPL couples (<35 years). The cumulative clinical outcomes of iRPL couples were comparable between the PGT-A and conventional IVF/ICSI groups. No significant differences were found in any clinical outcomes between the PGT-A and conventional IVF/ICSI groups for young or AMA couples with iRIF. In conclusion, NGS-based PGT-A involving TE biopsy may be useful for iRPL women to shorten the time to pregnancy and reduce their physical and psychological burden, especially for iRPL women with AMA; however, couples with iRIF may not benefit from PGT-A treatment. Considering the small sample size of the iRIF group, further investigations with a larger sample size are needed to verify our findings.